�Less than a year into the process, RamSoft, a starring developer of affordable healthcare information technology, has successfully helped PresGar, the nation's largest privately-owned medical imaging service company, establish a significant digital mammography comportment at eight-spot of its imaging centers.
The solution has been increased efficiency among PresGar mammographers and technologists and substantial nest egg for the company. If things go as planned, a one-ninth center may soon join the flux, combining RamSoft's PowerServer PACS and Gateway Routers with PresGar's new digital mammography system.
"It's a home run," Dave Kost, Imaging Informatics Manager for PresGar, said of the integration. "We couldn't be happier."
PresGar, of Tampa, FL, operates 36 imaging centers that complete an estimated 350,000 exams yearly. To facilitate optimal viewing, 10 PowerServer PACS, some serving more than one imaging center, along with three Gateway Routers receive been installed by RamSoft, of Toronto, Ontario, Canada.
The digital effort began in October 2007 when the first new mammography system was integrated with the RamSoft technology. Seven other systems were added through mid-2008, and a ninth system will be implemented afterward this year. The young digital mammography systems, in New York, Virginia, Ohio and Florida, are replacing film-screen mammography units at each center.
"PresGar was really our first big account in terms of establishing our solution as ideal for a distributed outpatient imaging center grouping," said Vijay Ramanathan, President and CEO of RamSoft. "The relationship has allowed us to prove that our solution is superior to anything else in that genial of environment."
In making the move to digital, PresGar had one predominate goal: to enable the capture of superior images that john be manipulated for optimum viewing victimisation the RamSoft mammography module. The PACS facilitates both on-site viewing and transmittance to remote locations for off-site limited review.
Offered in several configurations, the PowerServer provides a reliable, fault-tolerant, web-based approach to PACS, accommodating inexhaustible users and workstations. Features range from study trailing from start to finish and unmated real-time worklist flexibility, to prefetching of current and prior studies and elastic viewing protocols specific to modality and body office. A suite of clinical tools intentional to optimize images and a digital dictation module also are provided.
An important constituent is RamSoft's mammography module, which automatically sorts left wing and right digital image series and matches them to prior films for easy comparing.
"What we've done is make digital mammography function similarly to all of the other modalities offered by PresGar," Ramanathan aforementioned. "That has eliminated the need for them to make a separate, pricy investment in mammography. No longer does a company such as PresGar want to have one solution for all of the modalities and a separate solution for mammography."
In less than a year the RamSoft collaboration already has benefited PresGar. The company saved hundreds of thousands of dollars by opting not to purchase dedicated workstations; film has been eliminated, also delivery PresGar a substantial amount of money; technologists and mammographers ar more efficient, enabling more studies to be realized and revenues to increase; the tone of images captured has been enhanced, increasing reader confidence and minimizing liability; and images can be quickly and easily transmitted to remote locations. Clearly, RamSoft is playing an important theatrical role in PresGar's transition to digital mammography and boilers suit growth.
Numbers underscore that. Between 40 and 50 studies are completed day-after-day at each site compared with 18 to 20 per day a year ago. PresGar's overall efficiency has increased by 30%-40%.
"Digital mammography combined with RamSoft PACS has saved us tens of thousands of dollars beyond the workstation savings, and that's a big deal," Kost aforesaid. "Imaging centers face a very tough climate these days, and we have to do what we can to be efficient and profitable. RamSoft PACS and its Gateway Routers have at rest a long way toward helping us achieve that."
About RamSoft
RamSoft, Inc. is a leading healthcare IT software and services company that is dedicated to creating and delivering award-winning medical imagination and radioscopy solutions to its clients in the U.S. and around the world. The company's goal is to enable tomography facilities, radioscopy centers, ambulatory and acute-care practices to offer a superior floor and quality of patient role care with the affordable and feature-rich PowerServer� Series of PACS, RIS/PACS, teleradiology, and patient information management systems.
RamSoft
More information
Sunday, 7 September 2008
Thursday, 28 August 2008
Ed Sells Home
Former Tonight show buddy Ed McMahon has in agreement to sell his home � and not to Donald Trump!
Howard Bragman, Ed's spokesman, says that a deal has been reached on the California domiciliation � which is in the same neighborhood as Britney Spears' pad � and that Ed will be moving out when the sale is complete.
After Ed defaulted on a $4.8 million loan and faced foreclosure, Donald Trump had offered to buy the house and act as landlord.
We're not sure we'd want our landlord yelling "You're fired!" either.
�
More info
Monday, 18 August 2008
Ardea Biosciences Presents Phase 2a Antiviral Activity Data For Lead HIV Candidate, RDEA806 At XVII International AIDS Conference
�Ardea
Biosciences, Inc. (Nasdaq: RDEA) announced that information was presented
from its completed Phase 2a proof-of-concept monotherapy study of RDEA806,
the Company's novel investigational non-nucleoside reverse transcriptase
inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV),
demonstrating robust antiviral activity with a well-tolerated visibility. An
oral presentation of the data was granted today by Dr. Graeme Moyle, Director
of HIV Research, Chelsea and Westminster Hospital, during a late breaker
session at the XVII International AIDS Conference in Mexico City.
"We are extremely pleased that the last results of the Phase 2a sketch
presented today demonstrate that 800 mg once day-after-day produced like viral
burden reductions as 400 mg twice daily, providing last confirmation that
RDEA806 workings equally well given either once or twice everyday. Based on the
data to date, we continue to consider that RDEA806 has the potential to be a
first-line therapy for the treatment of HIV," aforementioned Barry D. Quart, PharmD,
Ardea's President and CEO. "We look forward to further evaluating RDEA806
and are on track to begin a Phase 2b study comparing once day-to-day doses of
RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients
receiving ground treatment with Truvada(R) (emtricitabine and tenofovir
disoproxil fumarate), in the third quarter of this year. A recently
completed drug interaction study with RDEA806 and Truvada confirmed the
want of drug-drug interactions between these agents, paving the way for
initiation of the Phase 2b written report."
The Phase 2a randomized, double-blind, placebo-controlled trial
evaluated the antiviral agent activity, pharmacokinetics, safety and tolerability
of once- and twice-daily oral dosing regimens of RDEA806 versus placebo in
48 HIV-positive patients who were naive to antiretroviral treatment. Nine
out of 12 patients in each of four cohorts received RDEA806. The primary
efficacy end point was the change from baseline in plasma viral payload.
Results from all tetrad cohorts showed a medial reduction in plasma viral
load at nadir of 1.8 - 2.0 log copies/mL. There were no serious adverse
events, premature discontinuations, clinically relevant ECGs changes or
drug-related rash reported in any age bracket. The incidence of CNS side effects
was like between do drugs and placebo. Gastrointestinal position effects were
most uncouth, but these effects were generally transient and mild.
The presentation is uncommitted on the conference site
(http://www.aids2008.org) and on the Company website
(hypertext transfer protocol://www.ardeabio.com) under the title "Antiviral action of RDEA806, a
novel HIV non-nucleoside reverse rNA polymerase inhibitor, in treatment of
naive HIV patients."
About RDEA806
RDEA806 is a novel non-nucleoside blow transcriptase inhibitor
(NNRTI) for the voltage treatment of HIV infection. Based on preclinical
and clinical studies to-date, we believe that RDEA806 may have important
competitive advantages compared to currently available NNRTIs. These
include the potential for potent antiviral agent activity against a wide range of
HIV viral isolates, including those that are repellent to efavirenz
(Sustiva(R)) and other presently available NNRTIs; a high genetic barrier
to resistance; no reproductive toxicity based on beast studies; the
potential to be administered in a patient-friendly, unwritten dosing regimen;
limited pharmacokinetic interactions with other drugs; and the ability to
be co-formulated with other HIV antiviral agent drugs.
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a ergonomics
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, urarthritis, cancer and inflammatory
diseases. We take four production candidates in clinical trials and others in
preclinical development and discovery. Our most advanced product nominee
is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for
the treatment of patients with HIV. We have evaluated our second-generation
NNRTI for the treatment of HIV, RDEA427, in a human micro-dose
pharmacokinetic study and have selected it for clinical development.
RDEA594, our lead product candidate for the treatment of gout, is in
preclinical development. We are currently evaluating our lead MEK
inhibitor, RDEA119, in a Phase 1 written report in advanced cancer patients and have
completed a Phase 1 study in normal healthy volunteers as a herald to
trials in patients with inflammatory diseases. Lastly, we stimulate evaluated
our second-generation MEK inhibitor for the treatment of genus Cancer and
seditious diseases, RDEA436, in a human micro-dose pharmacokinetic study
and have selected it for clinical development.
Statements contained in this press release regarding matters that are
non historical facts are "innovative statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
dissent materially from those expressed or implied by such forward-looking
statements. Such statements include, simply are non limited to, statements
regarding our goals, including the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the
results of preclinical, clinical and other studies. Risks that contribute
to the uncertain nature of the forward-looking statements include: risks
related to the issue of presymptomatic and clinical studies, risks related
to regulatory approvals, delays in commencement of preclinical and clinical
studies, and costs associated with our do drugs discovery and development
programs and line of work development activities. These and other risks and
uncertainties are described more fully in our most recently filed SEC
documents, including our Annual Report on Form 10-K and our Quarterly
Reports on Form 10-Q, under the headings "Risk Factors." All
advanced statements contained in this press tone ending speak only if as of
the appointment on which they were made. We undertake no obligation to update such
statements to reflect events that come or luck that exist after
the date on which they were made.
Ardea Biosciences, Inc.
http://www.ardeabio.com
View dose information on Sustiva.
More info
Biosciences, Inc. (Nasdaq: RDEA) announced that information was presented
from its completed Phase 2a proof-of-concept monotherapy study of RDEA806,
the Company's novel investigational non-nucleoside reverse transcriptase
inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV),
demonstrating robust antiviral activity with a well-tolerated visibility. An
oral presentation of the data was granted today by Dr. Graeme Moyle, Director
of HIV Research, Chelsea and Westminster Hospital, during a late breaker
session at the XVII International AIDS Conference in Mexico City.
"We are extremely pleased that the last results of the Phase 2a sketch
presented today demonstrate that 800 mg once day-after-day produced like viral
burden reductions as 400 mg twice daily, providing last confirmation that
RDEA806 workings equally well given either once or twice everyday. Based on the
data to date, we continue to consider that RDEA806 has the potential to be a
first-line therapy for the treatment of HIV," aforementioned Barry D. Quart, PharmD,
Ardea's President and CEO. "We look forward to further evaluating RDEA806
and are on track to begin a Phase 2b study comparing once day-to-day doses of
RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients
receiving ground treatment with Truvada(R) (emtricitabine and tenofovir
disoproxil fumarate), in the third quarter of this year. A recently
completed drug interaction study with RDEA806 and Truvada confirmed the
want of drug-drug interactions between these agents, paving the way for
initiation of the Phase 2b written report."
The Phase 2a randomized, double-blind, placebo-controlled trial
evaluated the antiviral agent activity, pharmacokinetics, safety and tolerability
of once- and twice-daily oral dosing regimens of RDEA806 versus placebo in
48 HIV-positive patients who were naive to antiretroviral treatment. Nine
out of 12 patients in each of four cohorts received RDEA806. The primary
efficacy end point was the change from baseline in plasma viral payload.
Results from all tetrad cohorts showed a medial reduction in plasma viral
load at nadir of 1.8 - 2.0 log copies/mL. There were no serious adverse
events, premature discontinuations, clinically relevant ECGs changes or
drug-related rash reported in any age bracket. The incidence of CNS side effects
was like between do drugs and placebo. Gastrointestinal position effects were
most uncouth, but these effects were generally transient and mild.
The presentation is uncommitted on the conference site
(http://www.aids2008.org) and on the Company website
(hypertext transfer protocol://www.ardeabio.com) under the title "Antiviral action of RDEA806, a
novel HIV non-nucleoside reverse rNA polymerase inhibitor, in treatment of
naive HIV patients."
About RDEA806
RDEA806 is a novel non-nucleoside blow transcriptase inhibitor
(NNRTI) for the voltage treatment of HIV infection. Based on preclinical
and clinical studies to-date, we believe that RDEA806 may have important
competitive advantages compared to currently available NNRTIs. These
include the potential for potent antiviral agent activity against a wide range of
HIV viral isolates, including those that are repellent to efavirenz
(Sustiva(R)) and other presently available NNRTIs; a high genetic barrier
to resistance; no reproductive toxicity based on beast studies; the
potential to be administered in a patient-friendly, unwritten dosing regimen;
limited pharmacokinetic interactions with other drugs; and the ability to
be co-formulated with other HIV antiviral agent drugs.
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a ergonomics
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, urarthritis, cancer and inflammatory
diseases. We take four production candidates in clinical trials and others in
preclinical development and discovery. Our most advanced product nominee
is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for
the treatment of patients with HIV. We have evaluated our second-generation
NNRTI for the treatment of HIV, RDEA427, in a human micro-dose
pharmacokinetic study and have selected it for clinical development.
RDEA594, our lead product candidate for the treatment of gout, is in
preclinical development. We are currently evaluating our lead MEK
inhibitor, RDEA119, in a Phase 1 written report in advanced cancer patients and have
completed a Phase 1 study in normal healthy volunteers as a herald to
trials in patients with inflammatory diseases. Lastly, we stimulate evaluated
our second-generation MEK inhibitor for the treatment of genus Cancer and
seditious diseases, RDEA436, in a human micro-dose pharmacokinetic study
and have selected it for clinical development.
Statements contained in this press release regarding matters that are
non historical facts are "innovative statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
dissent materially from those expressed or implied by such forward-looking
statements. Such statements include, simply are non limited to, statements
regarding our goals, including the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the
results of preclinical, clinical and other studies. Risks that contribute
to the uncertain nature of the forward-looking statements include: risks
related to the issue of presymptomatic and clinical studies, risks related
to regulatory approvals, delays in commencement of preclinical and clinical
studies, and costs associated with our do drugs discovery and development
programs and line of work development activities. These and other risks and
uncertainties are described more fully in our most recently filed SEC
documents, including our Annual Report on Form 10-K and our Quarterly
Reports on Form 10-Q, under the headings "Risk Factors." All
advanced statements contained in this press tone ending speak only if as of
the appointment on which they were made. We undertake no obligation to update such
statements to reflect events that come or luck that exist after
the date on which they were made.
Ardea Biosciences, Inc.
http://www.ardeabio.com
View dose information on Sustiva.
More info
Friday, 8 August 2008
Virtual Audio Project
Artist: Virtual Audio Project
Genre(s):
New Age
Electronic
Discography:
Virtual World
Year:
Tracks: 10
Time
Year:
Tracks: 11
Psychosis
Year:
Tracks: 9
Nightmares
Year:
Tracks: 9
Network
Year:
Tracks: 10
Mind Contact
Year:
Tracks: 14
Metropolis
Year:
Tracks: 10
Love
Year:
Tracks: 12
Legend
Year:
Tracks: 8
Jurassic
Year:
Tracks: 9
Impact
Year:
Tracks: 16
Hypnotic
Year:
Tracks: 11
Hot Sex
Year:
Tracks: 13
Genetics
Year:
Tracks: 10
Future
Year:
Tracks: 10
Fantasy
Year:
Tracks: 10
Exploration
Year:
Tracks: 13
Ego
Year:
Tracks: 12
Discovery
Year:
Tracks: 9
Alien
Year:
Tracks: 12
Adrenaline
Year:
Tracks: 12
Acceleration
Year:
Tracks: 15
Abyss
Year:
Tracks: 9
Tuesday, 1 July 2008
Markus Schulz
Artist: Markus Schulz
Genre(s):
Trance
Discography:
Progression
Year: 2007
Tracks: 1
Global Dj Broadcast
Year: 2007
Tracks: 10
Global_DJ Broadcast (incl Solar Stone Guestmix)
Year: 2006
Tracks: 1
Global DJ Broadcast (Incl Airwave Guestmix)
Year: 2006
Tracks: 1
Global DJ Broadcast (Incl Harry Lemon Guestmix)
Year: 2005
Tracks: 1
Global DJ Broadcast (Incl Christopher Lawrence Guestmix)
Year: 2005
Tracks: 1
Coldharbour Sessions 2004
Year: 2004
Tracks: 1
Denied: No June Wedding for Depp
Thursday, 19 June 2008
Mark Wahlberg - Wahlberg Hints At Durham Marriage
Actor MARK WAHLBERG has hinted at plans to wed his longtime girlfriend RHEA DURHAM, after referring to the mother of his children as his "future wife" at a New York event on Tuesday (10Jun08).
The couple has been dating since 2001 and has two children together - daughter Ella, four, and Michael, two.
Durham is currently pregnant with their third child - and Wahlberg appears to have marriage on his mind.
Wahlberg was attending the New York premiere of his new movie The Happening when he let slip about his wedding plans.
When asked about his 37th birthday celebrations on 5 June (08), he told People.com, "I had a beautiful day with my kids and my future wife. We went to brunch."
Of their impending arrival, the Boogie Nights star adds, "We're thrilled!"
See Also
Sunday, 8 June 2008
Little Man Tate
Artist: Little Man Tate
Genre(s):
Indie
Rock
Discography:
About What You Know
Year: 2007
Tracks: 11
Man I Hate Your Band
Year: 2006
Tracks: 12
Inexplicably taking their appoint from a saccharine 1991 flick nigh a baby portent leading Jodie Foster, Little Man Tate is a scrappy indie careen band from Sheffield, England. Like their Yorkshire compatriots the Arctic Monkeys, Little Man Tate offers a veddy veddy British ingest on guitar pop. But where the Arctic Monkeys' inspiration lies principally in the Television Personalities (so much so that in 2006 a rumor flew about the Internet that the TVPs' Daniel Treacy was in fact the band's privy ballad maker) and their brand of fractured post-punk, Little Man Tate shares more in common with Blur, the Dentists, and other devotees of the Kinks' blend of tricky tunes and playful lyrics about daily British animation. Singer and rhythm method guitar player Jon Windle, lead guitar player Edward "Maz" Marriot, bassist Ben Surtees, and drummer Dan Fields earlier formed under the list Carousel Moon in 2003, briefly exit through and through the name calling the Moon and Lazy Eye ahead settling on Little Man Tate in 2005. Little Man Tate released their debut single, "The Agent," in March 2006 on their own Yellow Van label. After a irregular self-released single, "What? What You Got," hit the take down reaches of the U.K. Top 40 graph in May of that year, Little Man Tate gestural to V2 Records. V2 released trey more than singles -- "Theater Party at Boothy's," "World, I Hate Your Band," and "Aphrodisiac in Latin" -- with increasing chart success each time, earlier Little Man Tate's debut record album, About What You Know, was released in February 2007.
Subscribe to:
Posts (Atom)